Document is current
Any future updates will be listed below
-
Authors
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
Luo, Yiming
O’Shea, John J.
Nakayamada, Shingo
- License Information
-
More Information
Article History
Accepted: 18 November 2021
First Online: 5 January 2022
Competing interests
: Y.T. has received speaking fees and/or honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers, Chugai, Eisai, Eli Lilly, Gilead, Mitsubishi-Tanabe and YL Biologics, and received research grants from Abbvie, Asahi-Kasei, Boehringer Ingelheim, Chugai, Corrona, Daiichi-Sankyo, Eisai, Kowa, Mitsubishi-Tanabe and Takeda, and consultant fees from AbbVie, Ayumi, Daiichi-Sankyo, Eli Lilly, GlaxoSmithKline, Sanofi and Taisho. S.N. has received speaking fees and/or honoraria from Asahi-kasei, Astellas, Boehringer Ingelheim, Bristol-Myers, GlaxoSmithKline, Pfizer and Sanofi, and has received research grants from Mitsubishi-Tanabe and Novartis. J.J.O. declares receipt of US patent royalties related to JAK inhibitors and NIH Cooperative Research and Development Agreement with Pfizer. Y.M.L. declares no competing interests.
